Nasdaq

Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor

Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
Hosted on MSN

FDA clears Tandem’s Control-IQ+ technology for type 2 diabetes

The US Food and Drug Administration (FDA) has cleared Tandem Diabetes Care’s Control-IQ+ technology, an automated insulin delivery algorithm, for use in individuals aged 18 and above with type 2 ...
Business Wire

Real-World Evidence Confirms Immediate and Ongoing Performance of the t:slim X2 Insulin Pump with Control-IQ Technology in Children and Adults

5 Adolfsson P, Björnsson V, Heringhaus A, Sjunnesson K. A Prospective Controlled Study Evaluating the Long-Term Outcomes on Glucose Control, Sleep, and Health Economy After Implementation of Tandem ...
Nasdaq

Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Business Wire

Tandem Diabetes Care Announces NEJM Publication of Study Demonstrating Increased Time in Range in Young Children with Type 1 Diabetes Using the t:slim X2 Insulin Pump with ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...